MedTrace Logo

Severe Neutropenia After HIPEC Using Mitomycin-C

NCT05513183 · Status: COMPLETED · Type: OBSERVATIONAL · Enrollment: 74

Last updated 2023-08-07

No results posted yet for this study

Summary

Mitomycin-C (MMC) is the most commonly used chemotherapeutic agent for hyperthermic intraperitoneal chemotherapy (HIPEC) after cytoreductive surgery (CRS) to treat colorectal cancer patients with peritoneal metastases. However, MMC has a side effect of myelosuppression. Particularly, severe neutropenia after CRS with HIPEC can be a life-threatening condition. Despite the postoperative risks of this side effect, the causes and risk factors for severe neutropenia after CRS followed by HIPEC is not identified so far. Therefore, in this study, we aimed to evaluate to evaluate clinical risk factors and pharmacologic properties after CRS with HIPEC using MMC in patients with colorectal cancer or appendiceal mucinous neoplasms with peritoneal metastases.

Conditions

  • Colorectal Cancer Metastatic
  • Cancer Metastatic to the Peritoneal Cavity
  • Appendiceal Neoplasm
  • Pseudomyxoma Peritonei

Interventions

PROCEDURE

Intraoperative blood and peritoneal fluid samplings during HIPEC

\- Intraoperative samplings of blood and peritoneal fluids during HIPEC : * Blood sampling of 5ml at each time point (baseline, 0 (HIPEC starting point), 15, 30, 45, 60, 75, 90, 120 min) * Peritoneal fluid sampline of 5ml at each time point (baseline, 0 (HIPEC starting point), 15, 30, 45, 60, 75, 90 min)

Sponsors & Collaborators

  • Gangnam Severance Hospital

    lead OTHER

Eligibility

Min Age
20 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2021-05-20
Primary Completion
2023-03-20
Completion
2023-03-20

Countries

  • South Korea

Study Locations

More Related Trials

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT05513183 on ClinicalTrials.gov